Unité de Thérapie Cellulaire et banque de Tissus, CHRU de Nancy, Vandœuvre-lès-Nancy, France.
INSERM, Vandœuvre-lès-Nancy, France.
Stem Cells. 2017 Dec;35(12):2331-2339. doi: 10.1002/stem.2695. Epub 2017 Sep 16.
Sepsis and septic shock are the leading cause of admission and mortality in non-coronary intensive care units. Currently, however, no specific treatments are available for this syndrome. Due to the failure of conventional treatments in recent years, research is focusing on innovative therapeutic agents, including cell therapy. One particular type of cell, mesenchymal stromal/stem cells (MSCs), has raised hopes for the treatment of sepsis. Indeed, their immunomodulatory properties, antimicrobial activity and capacity of protection against organ failure confer MSCs with a major advantage to treat the immune and inflammatory dysfunctions associated with sepsis and septic shock. After a brief description of the pathophysiology of sepsis and septic shock, the latest advances in the use of MSCs to treat sepsis will be presented. Stem Cells 2017;35:2331-2339.
脓毒症和感染性休克是非冠状动脉重症监护病房住院和死亡的主要原因。然而，目前针对这种综合征尚无特定的治疗方法。由于近年来常规治疗的失败，研究的重点是创新的治疗药物，包括细胞疗法。一种特殊类型的细胞，间充质基质/干细胞（MSCs），为脓毒症的治疗带来了希望。事实上，它们的免疫调节特性、抗微生物活性以及防止器官衰竭的能力使 MSCs 具有治疗与脓毒症和感染性休克相关的免疫和炎症功能障碍的主要优势。在简要描述脓毒症和感染性休克的病理生理学之后，将介绍使用 MSCs 治疗脓毒症的最新进展。干细胞 2017;35:2331-2339.
